Research Article| Volume 40, ISSUE 4, P505-517, October 1989

A longitudinal study on cortisol, prolactin and thyroid hormones in users of norplantR subdermal implants or a copper T device

      This paper is only available as a PDF. To read, Please Download here.


      A longitudinal study was undertaken to assess PRL, cortisol, TSH, T3 and T4 levels in NORPLANT4 implant users (n = 22) and Copper T users (n = 20). Participants were healthy women with no contraindication for hormonal contraception. Samples were drawn at 0930 to 1000 h twice pretreatment and at month 2, 4, 6, 12, 24 and 36 after insertion. At the second treatment month, a second sample was obtained at 1600 h to assess cortisol diurnal variation. Hormones were measured by RIA.
      Values for all hormones were similar in NORPLANTR and Copper T users. No significant changes occurred throughout the study period. Elevated PRL levels (>500 mU/1) were found in three women from each group before and during treatment but no clinical evidence of hyperprolactinemia was detected.
      The results of this study reassure that long-term use of NORPLANTR implants do not impair plasma levels of cortisol, prolactin and thyroid hormones.
      To read this article in full you will need to make a payment

      Purchase one-time access:

      Academic & Personal: 24 hour online accessCorporate R&D Professionals: 24 hour online access
      One-time access price info
      • For academic or personal research use, select 'Academic and Personal'
      • For corporate R&D use, select 'Corporate R&D Professionals'


      Subscribe to Contraception
      Already a print subscriber? Claim online access
      Already an online subscriber? Sign in
      Institutional Access: Sign in to ScienceDirect


        • Croxatto HB
        • Díaz S
        • Roberton DN
        • Pavez M
        Clinical chemistry in women treated with levonorgestrel implants NORPLANTR or TCu 200 IUD.
        Contraception. 1983; 27: 281-288
        • Johansson EDB
        • Odlind V
        NORPLANTR: Biochemical effects.
        in: Mishell DR Long-Acting Steroid Contraception. Raven Press, New York1983: 117-125
        • Robertson DN
        Norgestrel-releasing silastic rods: Clinical effects, biochemical effects and in vivo release rates.
        in: Mishell DR Long-Acting Steroid Contraception. Raven Press, New York1983: 127-147
        • Shaaban MM
        • Elwan SI
        • El-Sharkawy MM
        • Farghaly AS
        Effect of subdermal levonorgestrel contraceptive implants, NORPLANTR, on liver functions.
        Contraception. 1984; 30: 407-412
        • Shaaban MM
        • Elwan SI
        • Abdalla SA
        • Darwish HA
        Effect of subdermal levonorgestrel contraceptive implants, NORPLANTR, on serum lipids.
        Contraception. 1984; 30: 413-419
        • Croxatto HB
        • Díaz S
        • Pavez M
        Clinical chemistry in women treated with six levonorgestrel covered rods or with a Copper IUD.
        Contraception. 1985; 31: 321-330
        • Holma P
        • Robertson DN
        Cholesterol and HDL-cholesterol values in women during use of subdermal implants releasing levonorgestrel.
        Contraception. 1985; 32: 163-171
        • Roy S
        • Mishell Jr, DR
        • Robertson DN
        • Krauss RM
        • Lacarra M
        • Duda MJ
        Long-term reversible contraception with levonorgestrel-releasing silastic rods.
        Am. J. Obstet. Gynecol. 1984; 148: 1006-1013
        • World Health Organization
        Facts about an implantable contraceptive.
        Bulletin of the World Health Organization. 1985; 63: 485-494
        • Díaz S
        • Pavez M
        • Robertson DN
        • Croxatto HB
        A three-year clinical trial with levonorgestrel silastic implants.
        Contraception. 1979; 19: 557-573
        • Bayad MA
        • Ibrahim II
        • Fayad MM
        • Hassanein AA
        • Hafez ESE
        • Abdalla MI
        Serum cortisol in women users of subdermal levonorgestrel implants.
        Contracept. Deliv. Syst. 1983; 4: 133-135
        • Shaaban MM
        • El-Nashar IM
        • Ghaneimah SA
        • Gomaa AA
        • Salah M
        • Abdel-Aleem AM
        Hormonal changes during the first year of use of subdermal levonorgestrel implants, NORPLANTR.
        Contraception. 1984; 30: 391-405
        • Angeli A
        • Dogliotti L
        Fibrocystic Disease of the Breast: A Revisit and New Perspectives.
        in: Elsevier Science Publishers B.V. (Excerpta Medica), Amsterdam1984: 15-37
        • Sivin I
        International experience with NORPLANTR and NORPLANTR-2 contraceptives.
        Stud. Fam. Plann. 1988; : 81-94
        • Who Special Programme of Research, Development and Research Training in Human Reproduction
        Programme for the Provision of Matched Assay Reagents for the RIA of Hormone in Reproductive Physiology.
        Method Manual. 1987; (11th Ed.)
        • Utiger RD
        in: Jaffe BM Berhmann HF Methods of Hormone Radioimmunoassay. Academic Press, New York1974: 161-164
        • Hunter WM
        Labelling of protein antigens.
        in: Hunter WM Corrie KFT Immunoassay for Clinical Chemistry. Churchill and Livingstone, London1983: 263-266
        • Chopra IJ
        • Solomon DH
        • Bell B
        Radioimmunoassay for measurement of triiodothyronine in human serum.
        J. Clin. Invest. 1971; 50: 2033-2041
        • Chopra IJ
        A radiolmmunoassay for measurement of thyroxine in unextracted serum.
        J. Clin. Endocrinol. Metab. 1972; 34: 938-947
      1. RIA Data Processing Basic Programs. Contributed by Rodbard D, Huston J, Munsen P.J. Biophysical Endocrinology Section. Endocrinology and Reproduction Research Branch. National Institute of Child Health and Human Development, NIH, Bethesda, Maryland, U.S.A.

      2. SAS/STAT Guide for Personal Computers. 6th Edition. SAS Institute Inc, Cary, NC., U.S.A1987 (Release 6.02)